October, 2011
01.. < > 02 (Chronic kidney disease CKD) Creatinine GFR.. < > 03.. < > 04.. < > - 2 -
2011 PD User Club / Continuous Education in Diagnostics 11 26 3F 2011 PD Continuous Education in Diagnostics :,, Reorganization of the lab: Consolidation, Optimization, Automation Point of Care Testing (POCT) POCT management and future trend in the hospital HE4 - HE4 -a new tool in ovarian cancer diagnostics Anti -CCP All you want to know about Anti-CCP and were afraid to ask :? Infectious disease positive or negative: what really matters! Procalcitonin- Clinical Utility of Procalcitonin, a marker protein for infection and sepsis Bone Markers Renaissance of Serum Markers in Bone Metabolisme Roche rita.wu@roche.com - 3 -
Roche Tina-quant Cystatin C (Chronic kidney disease CKD) Creatinine GFR (Glomerular filtration rate ) creatinine GFR Cystatin C CKD Creatinine CKD 3 50 Cystatin C 1 2 (Figure 1) Figure 1: Stages of chronic kidney disease according to NKF KDOQI 1 Cystatin C creatinine (Figure 2) Figure 2: ROC analysis of cystatin C and creatinine 2-4 -
Roche Tina-quant Cystatin C Figure 3: CV comparison of different manufacturers based on data of package insert Roche sandy.wang@roche.com 1. National kidney Foundation Kidney Disease Outcomes Quality Intiative, www.kidney.rog/professionals/kdoqi/. 2. Artunc, F., Fischer, I.U., Risler, T., Erley, C.M. (2005). Improved estimation of FGR by serum cystatin C in patients undergoing cardiac catherization. Int J Cardiol 102, 173-8. - 5 -
Elecsys S100 A valuable addition to the diagnosis of traumatic brain injury (Minor Traumatic Brain Injury) Glasgow Coma Score guideline Glasgow Coma Score 13 Computed Tomography; CT Glasgow Coma Score Glasgow Coma Score : 3-20% S100 S100 Elecsys S100 heterodimer S100 A1b homodimer S100BB S100 BBB 3 cut off 0.105 μg/l S100 Rule Out (GCS 13-15) Dr. Biberthaler 2006 S100 (Negative Predictive Value) 99.7% 1 S100 secondary - 6 -
Elecsys 2010/ cobas e411/e601 Modular E170 Total Turnaround Time Roche cally.hsieh@roche.com 1. Biberthaler, P. et al. (2006). Shock 25(5), 446-453 - 7 -
Elecsys TORCH TORCH Rubella IgG TORCH Toxoplasma gondii (Toxoplasma gondii) ( ) (tissue cysts) 1 ( ) 2,3 4,5,6 IgG IgM IgM IgG (IgG / IgM) 3,5 Rubella congenital Rubella syndrome CRS CRS CRS IgG - 8 -
IgM IgG 7,8,9,10,11,12,13 Cytomegalovirus 40-100% CMV CMV CMV 0.2-2.5% 10% CMV 1% 40% CMV HIV CMV CMV IgG CMV IgG IgM CMV IgM CMV IgG CMV IgM IgG CMV 14,15,16,17,18,19 TORCH? Roche TORCH : Rubella IgG Rubella IgM Toxo IgG Toxo IgM CMV IgG CMV IgM HSV cobas 4000 cobas 6000 cobas 8000 Roche TORCH rita.wu@roche.com - 9 -
1. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004;363:1965-1976. 2. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992;15:211-222. 3. Khalifa KES, Roth A, Roth B, Arasteh KN, Janitschke K. Value of PCR for Evaluationg Occurrence of Parasitemia in Immunocompromised Patients with Cerebral and Extracerebral Toxoplasmosis. J Clin Microbiol 1994;32:2813-2819. 4. Remington JS, Mc Leod R & Desmonts G 2001, Toxoplasmosis, 205-346, in J.S. Remington & J.O. Klein (ed.), Infectious Diseases of the Fetus and Newborn Infant, 5th ed. W.B. Saunders, Philadelphia, Pa. 5. Thulliez P. Maternal and foetal infection: in Toxoplasmosis (eds D.H.M. Joynson, T.G. Wreghitt) Cambridge University Press, 2001:193-213 ISBN 0521 44328 8. 6. Wong SY, Remington JS. Toxoplasmosis in pregnancy. Clin Infect Dis 1994;18:853-862. 7. Pustowoit B, Liebert UG. Predictive Value of Serological Tests in Rubella Virus Infection during Pregnancy. Intervirology 1998;41:170-177. 8. Cooper LZ, Alford CA. Rubella, in Infectious Diseases of the Fetus & Newborn Infant,: 5th Ed 2001, pp 347-88, ed Remington JS & Klein JO, Philadelphia: W.B. Saunders. 9. Banatvala JE, Brown DWG. Rubella. Lancet 2004;363:1127-1137. 10. Best JM, Banatvala JE. Rubella Principles and Practice of Clinical Virology, 4th edition, ed by Zuckerman AJ, Banatvala JE and Pattison JR 2000:387-418, John Wiley & Sons, Ltd. 11. Pustowoit B, Grangeot-Keros L, Hobman TC, Hofmann J. Evaluation of recombinant rubella-like particles in a ommercial immunoassay for the detection of anti-rubella IgG. Clin Diagn Virol 1996;5:13-20. 12. Detection and Quantitation of Rubella IgG Antibody: Evaluation and Performance Criteria for Multiple Component Test Products, Specimen Handling, and Use of Test Products in the Clinical Laboratory; Approved Guideline. NCCLS document I/LA6-A (ISBN) 1-56238-335-3. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 1997. 13. Skendzel L. Rubella Immunity. Defining the Level of Protective Antibody. Am J Clin Pathol 1996;106:170-174 14. Revello MG, Gerna G. Diagnosis and Management of Human Cytomegalovirus Infection in the Mother, Fetus, and Newborn Infant. Clin Microbiol Rev 2002;15(4):680-715. - 10 -
15. Munro SC, Hall B, Whybin LR, et al. Diagnosis of and Screening for Cytomegalovirus Infection in Pregnant Women. J Clin Microbiol 2005;43(9):4713-4718. 16. Lazzarotto T, Gabrielli L, Lanari M, et al. Congenital Cytomegalovirus Infection: Recent Advances in the Diagnosis of Maternal Infection. Hum Immunol 2004;65:410-415. 17. Guerra B, Simonazzi G, Banfi A, et al. Impact of diagnostic and confirmatory tests and prenatal counseling on the rate of pregnancy termination among women with positive cytomegalovirus immunoglobulin M antibody titers. Am J Obstet Gynecol 2007;196:221-223. 18. Duff P. A thoughtful algorithm for the accurate diagnosis of primary CMV infection in pregnancy. Am J Obstet Gynecol 2007;196:196-197. 19. Ljungman P. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Brit J Haematol 2004;125:107-116 0800-258-458 (www.roche.com.tw) - 11 -